Targeted Drug Delivery
Targeted Drug Delivery - Related Videos
03:30
Targeted Drug Delivery in a Mouse Model via Cisterna Magna Injection
0 Views •
2025
Source: Zamboni, M., et al., Induction of Leptomeningeal Cells Modification Via Intracisternal Injection. J. Vis. Exp. (2020)This video demonstrates the procedure of delivering an inducer drug into the cisterna magna of an anesthetized mouse. The injection selectively induces fluorescent marker expression in brain surface cells accessible via cerebrospinal fluid, confirmed by fluorescence imaging.
14:10
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
0 Views •
Cited by 15 •
2010
Insonation of microbubbles is a promising strategy for tumor ablation at reduced time-averaged acoustic powers, as well as for the targeted delivery of therapeutics. The purpose of the present study is to develop low duty cycle ultrasound pulsing strategies and nanocarriers to maximize non-thermal microvascular ablation and payload delivery to subcutaneous C6 gliomas.
01:24
Modified-Release Drug Delivery Systems: Site-Targeted
0 Views •
2026
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
07:00
Targeting of Deep Brain Structures with Microinjections for Delivery of Drugs, Viral Vectors, or Cell Transplants
0 Views •
Cited by 23 •
2010
In this article, we show a method to make glass capillary needles with a 50-μm lumen. This technique significantly reduces the brain damage, minimizes passive diffusion of drugs and allows a precise targeting into the rodent brain.
01:24
Site-Targeted Drug Delivery Systems: Polymeric Carriers
0 Views •
2026
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
FAQs
These components serve as carriers or molecular targeting elements that associate a medication with a biological destination. Antibodies and ligands can recognize markers associated with particular cells or diseased tissue, while nanoparticles can carry the drug and support its distribution. Their selection helps determine how selectively the payload reaches its intended site and how much healthy tissue is exposed.
Biological markers provide the recognition basis for directing medication toward specific cells or diseased tissue. A targeting element can be designed to recognize these markers, helping distinguish the intended site from healthy organs. This selectivity matters because the strategy aims to improve treatment efficacy while limiting unnecessary exposure elsewhere in the body.
Stimulus-responsive systems are designed to release their payload under defined local conditions rather than distributing it indiscriminately. The relevant condition acts as a trigger for local release, linking drug availability to the environment near the intended tissue. This mechanism supports controlled dosing and distribution, which are important goals in clinical research and therapeutic design.
The drug carrier, the molecular targeting element, the biological marker being recognized, and the local conditions that trigger release all influence therapeutic behavior. Together, these features guide where medication travels, which cells or tissues it encounters, and when the payload becomes available. Designing them in combination helps balance selective treatment with reduced exposure to healthy organs.
Development begins by pairing the medication with an appropriate carrier or targeting element, such as an antibody, ligand, nanoparticle, or stimulus-responsive system. Researchers then align that design with biological markers or defined local release conditions. The resulting approach can be evaluated according to its distribution, dosing, release behavior, potential efficacy, and exposure of healthy tissue.
The approach supports treatment development across several disease areas, including cancer, infections, inflammatory disorders, and other diseases. Its clinical relevance comes from directing medication more selectively toward diseased tissue or specific cells. By coordinating targeting with controlled distribution and release, researchers can design therapies intended to improve efficacy while reducing adverse effects associated with broader exposure.